Wedbush Assumes Coverage of Voyager With Outperform Rating
Wednesday Ends With Index Decline | Wall Street Today
FDA Investigating Safety Risks of Bluebird's Skysona
Wolfe's Short Ideas: Companies With Potential Dividend Cuts
Mizuho Maintains Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.5
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330